Stripe, Square, and PayPal all prohibit peptides and research chemicals in their terms of service — regardless of research-grade classification, UK legal status, or the customer base being served. The ban applies equally to suppliers selling to universities, laboratories, and registered research institutions. High-street banks apply the same categorical block without individual assessment. Provider appetite is the bottleneck, not compliance posture. GenerateFX pre-qualifies against real onboarding criteria before any application is submitted.
Stripe, Shopify Payments, PayPal, and Square prohibit peptides and research chemicals in their published terms of service. The ban is categorical — research-grade classification, end-customer type, and UK legal status are not considered. Most businesses discover the prohibition only after account closure, with funds held and no escalation route available.
Processor account closures in this sector are rarely preceded by meaningful warning. Funds are held for 90–180 days in rolling reserve wind-down. For businesses operating on regular supplier payment cycles — particularly those importing from international manufacturers — the cash flow impact of an unannounced freeze is immediate and severe. Recurring billing is refused outright by most specialist processors that will onboard the category at all.
The narrow pool of processors that will onboard peptide and research chemical businesses charge 5–8% — often higher for newer businesses or those with prior account closures — with rolling reserves of 10–15% on top. These rates are not driven by the actual risk profile of research-grade suppliers: they reflect the thin competition in a deliberately under-served market.
Provider appetite is the primary constraint in this sector — not compliance. GenerateFX pre-qualifies peptide and research chemical businesses against current onboarding criteria before introductions are made. We cover card acquiring for research-grade suppliers, named IBAN accounts, recurring billing infrastructure where acquirer appetite exists, and international payment routing for B2B research procurement.
Card acquiring for research-grade suppliersProcessors with active peptide and research chemical onboarding capability — pre-qualified against current intake criteria, not published category lists. We assess whether recurring billing and subscription processing are available for the specific business model before any application is submitted.
Named IBAN accounts for peptide businessesSpecialist EMI and banking providers that actively onboard research chemical and peptide suppliers — providing named IBAN accounts rather than pooled payment infrastructure, with stability appropriate for regular B2B supplier payment cycles.
International payment routing for B2B research procurementCross-border payment infrastructure for businesses importing from manufacturers in China, Germany, or the US — including wire transfer capability that avoids the correspondent bank interference that systematically affects this category at SWIFT level.
Recurring billing infrastructureWhere acquirer appetite for recurring billing exists in this sector, we identify it and structure the introduction accordingly — reducing the operational fragility of businesses relying on one-off card transactions for what are effectively regular institutional procurement relationships.
A UK peptide supplier with £250k/month in revenue, selling exclusively to registered research institutions and university laboratories on purchase order. Primary processor closed the account with 7 days notice — the B2B, research-grade customer base was not a factor. £60k held in rolling reserve. Four replacement processor applications declined.
A UK research chemical distributor with a predominantly US customer base — academic institutions and private research facilities. Card acquiring declined on application by three processors citing ToS. US customers requesting ACH and wire options rather than card, but no banking infrastructure in place to support USD receipt and international wire origination.
A UK peptide distributor importing from manufacturers in China and Germany under formal supply agreements. SWIFT payments flagged and held by correspondent bank — three consecutive supplier payments delayed, putting supply agreements at risk. Domestic bank unable to resolve the correspondent bank interference.
Tell us about your operation or the client situation. We will assess whether there is a suitable provider match and come back to you directly. No obligation, no hard sell.
Have a client in this sector?If you're an EMI, MSB, payment consultant, or adviser with clients in this space you can't service directly — we have a structured introducer arrangement.